+1 973 564 7555 [email protected]
ISO 13485:2016   MDSAP MD 1243914-1
Global Offices:
  • U.S.
  • Germany
  • Russia
    • Moscow
    • Saint Petersburg
  • Poland
  • Czech Republic
0 Items
DRG International, Inc.
  • Products
    • DRG:HYBRiD-XL®
    • Hepcidin 25 (bioactive) HS
    • Salivary ELISA Kits
    • CHROMagar
    • RUO ELISAs
    • Health Canada Registered
    • Ameritox Labs
  • Distribution
  • Newsroom
    • News
    • Media
    • Events
  • Reference Library
  • About Us
    • General Information
    • History Timeline
  • Contact Us
Select Page

An adverse immune-endocrine profile in patients with tuberculosis and type 2 diabetes.

Abstract Diabetes is a risk factor for the development of pulmonary tuberculosis (TB) and both diseases present endocrine alterations likely to play a role in certain immuno-endocrine-metabolic associated disorders. Patients with TB, or with TB and type 2 diabetes (TB + T2DM) and healthy controls (HCo) were assessed for plasma levels of cortisol, dehydroepiandrosterone (DHEA), estradiol, testosterone, growth hormone (GH), prolactin, insulin-like growth factor-1 (IGF-1), cytokines (IL-6, IL-10, IFN-γ) and the specific lymphoproliferative capacity of peripheral blood mononuclear cells. All patients had higher levels of cortisol with a reduction in DHEA, thus resulting in an increased cortisol/DHEA ratio (Cort/DHEA). Increased prolactin and particularly GH levels were found in both groups of TB patients. This was not paralleled by increased concentrations of IGF, which remained within the levels of HCo. Estradiol levels were significantly augmented in patients TB, and significantly more in TB + T2DM, whereas testosterone levels were decreased in both groups of patients. IFN- γ and IL-6 concentrations were significantly increased in all TB, even further in TB + T2DM; while IL-10 was equally increased in both groups of TB patients. The in vitro specific proliferative capacity was decreased in both groups of patients as compared to that of HCo. The adverse immune-endocrine profile of TB seems to be slightly more pronounced in patients who also have T2DM.

DRG product(s) used in the study above

You can view the product details and buy it now

Testosterone Estradiol DHEA Fernández R1, Díaz A1, D'Attilio L1, Bongiovanni B1, Santucci N1, Bertola D2, Besedovsky H3, Del Rey A3, Bay ML1, Bottasso O4.

Author Information

Instituto de Inmunología Clínica y Experimental de Rosario, UNR-CONICET, Suipacha 590, Rosario, 2000, Santa Fe, Argentina.
Servicio de Clínica Médica, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina.
Institute of Physiology and Pathophysiology, Philipps University, Faculty of Medicine, Marburg, Germany.
Instituto de Inmunología Clínica y Experimental de Rosario, UNR-CONICET, Suipacha 590, Rosario, 2000, Santa Fe, Argentina. Electronic address: [email protected].
Tuberculosis (Edinb). 2016 Dec;101:95-101. doi: 10.1016/j.tube.2016.09.001. Epub 2016 Sep 12.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Link: https://www.ncbi.nlm.nih.gov/pubmed/27865406

by Gary Khodanian | Sep 12, 2016

 
  • Events
  • News
  • Products
  • Uncategorized

DRG International, Inc.

841 Mountain Avenue
Springfield, NJ 07081 USA

Tel: +1-973-564-7555
Fax: +1-973-564-7556

Copyright © 2022.
DRG International Inc.
All Rights Reserved.
PCI Compliance Certification

Subsidiaries

  • USA
  • Germany
  • Russia – Moscow
  • Russia – St Petersburg
  • Poland
  • Czech Republic

Support

  • Order Information
  • Troubleshooting

Shortcuts

  • Login
  • Terms of Use
  • Privacy Policy
  • Privacy Preferences
  • Privacy Policy
  • Cookie Policy
  • Facebook
  • Twitter
  • Google
  • RSS
  • linkedin
  • instagram

Designed by Walnut St. Labs